Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety
Executive Summary
The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.
You may also be interested in...
Ventyx Won’t Pursue Psoriasis Further Despite Phase II Success
Ventyx’s TYK2 inhibitor met primary and secondary endpoints in a Phase II psoriasis trial, but the biotech determined the data are not competitive in a class led by Bristol’s Sotyktu.
BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu
Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.
Finance Watch: Neuron23 Adds $100m To Take First Drug Into The Clinic
Private Company Edition: Westlake Village BioPartners-founded Neuron23 will take the LRRK2 inhibitor NEU-723 for Parkinson’s disease into human testing before the end of 2022. Also, Celsius raised $83m in fresh VC cash and ITM added another €33m to its recent €25m equity financing.